ALB and Hypoalbuminemia: We found that post-treatment hypoalbuminemia was a significant prognostic factor to predict short PFS and OS in patients with mRCC who received sunitinib or sorafenib as first-line targeted therapy; integrating post-treatment serum albumin level into the basic MSKCC risk model may improve the accuracy of the MSKCC model in predicting patient overall survival and progression-free survival.